Autopsy report · NCT04394286
A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects
Cause of deathFunding or business
“Takeda has decided to not further develop the SHP648 (TAK-748) program. No subjects have been dosed with SHP648. The decision to terminate study SHP648-101 is not due to any safety concerns.”
Life of this trial
- Ran for about 1 year before it stopped.
- 2 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Baxalta now part of Shire
- Sponsor type
- Industry
- Conditions
- Hemophilia B
- Interventions
- SHP648
- Participants
- 2
- Sites
- 2
- Countries
- Spain, Turkey (Türkiye)
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.